Animal cells and systems

  • 제15권1호
  • /
  • Pages.9-17
  • /
  • 2011
  • /
  • 1976-8354(pISSN)
  • /
  • 2151-2485(eISSN)
한국통합생물학회 (The Korean Society for Integrative Biology)
권호 표지
DOI QR코드

DOI QR Code

Sequential administration of camptothecin sensitizes human colon cancer HCT116 cells to paclitaxel via $p21^{Cip1/WAF1}$

  • 투고 : 2010.10.26
  • 심사 : 2010.12.15
  • 발행 : 2011.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Colorectal cancer is the third leading cause of cancer-related death in Western countries. Chemotherapeutic agents with different mechanisms of action have shown an increase in cure rates. In the present study, we investigated the effect of a combination of low concentration of paclitaxel (taxol, 5 nM) and topoisomerase 1 inhibitor camptothecin (CPT) on HCT116 colon cancer cells. Although the viability of cells treated with taxol alone was similar to that of control cells, sequential treatment with taxol and CPT exhibited high cytotoxicity. However, the opposite sequence of treatment did not exert cytotoxic effects on HCT116 cells. This enhanced cytotoxicity of the sequential combination therapy was the result of mitotic arrest, which increased the level of $p21^{Cip1/WAF1}$ through the p38 mitogen-activated protein kinase (MAPK) pathway. Knockdown by $p21^{Cip1/WAF1}$ siRNA or treatment with a p38 inhibitor reduced the viability of cells sequentially exposed to taxol and CPT. Taken together, a low taxol concentration in combination with CPT induced mitotic arrest in HCT116 cells, leading to synergistic cell death through enhanced expression of $p21^{Cip1/WAF1}$ and p38 MAPK pathway. Therefore, taxol could playa role as a sensitizer of CPT in colon cancer cells.

키워드

참고문헌

  1. Abal M, Bras-Goncalves R, Judde JG, Fshihi H, De Cremoux P, Louvard D, Magdelenat H, Robine S, Poupon MF. 2004. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene. 23: 1737-1744. https://doi.org/10.1038/sj.onc.1207299
  2. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. 2001. Taxolinduced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 20:147-155. https://doi.org/10.1038/sj.onc.1204062
  3. Bahadori HR, Green MR, Catapano CV. 2001. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol. 48:188-196. https://doi.org/10.1007/s002800100327
  4. Bathe OF, Ernst S, Sutherland FR, Dixon E, Butts C, Bigam D, Holland D, Porter GA, Koppel J, Dowden S. 2009. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for color ectal liver metastases. BMC Cancer. 9: 156. https://doi.org/10.1186/1471-2407-9-156
  5. Borbe R, Riger J, Weller M. 1999. Failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status. Cancer Chemother Pharmacol. 44: 217-227. https://doi.org/10.1007/s002800050970
  6. Chen YG, Cipriano SC, Arenkiel JM, Miller FR. 1995. Tumor suppressing by p21WAF1 undergo normal development but are defective in G I checkpoint control. Cell. 82: 675-784. https://doi.org/10.1016/0092-8674(95)90039-X
  7. Ciccarelli C, Marampon F, Scoglio A, Mauro A, Giacinti C, De Cesaris P, Zani BM. 2005. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiationand onco-phenotype reversal in rhabdomyosarcoma cells. Mol Cancer. 4:41. https://doi.org/10.1186/1476-4598-4-41
  8. Cui X, Zhang J, Ma P, Myers DE, Goldberg IG, Sittler KJ, Barb JJ, Munson PJ, Cintron AP, McCoy JP, ct al. 2005. cGMP-independent nitric oxide signaling and regulation of the cell cycle. BMC Genomics. 6:151. https://doi.org/10.1186/1471-2164-6-151
  9. Deacon K, Mistry P, Chernoff J, Blank JL, Patel R. 2003. p38 mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates dell survival during chemotherapeutic drug-induced mitotic arrest. Mol Biol Cell. 14: 2071-2087. https://doi.org/10.1091/mbc.E02-10-0653
  10. Downes CS, Mullinger AM, Johnson RT. 1991. Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis. Proc. Nati. Acad. Sci USA. 88: 8895-8899. https://doi.org/10.1073/pnas.88.20.8895
  11. Fishman AD, Wadler S. 2001. Advances in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 1: 20-35. https://doi.org/10.3816/CCC.2001.n.002
  12. Fuchs C, Mitchell EP, Hoff PM. 2006. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 32: 491-503. https://doi.org/10.1016/j.ctrv.2006.07.001
  13. Furuta T, Hayward RL, Meng LH, Takemura H, Aune GJ, Bonner WM, Aladjem MI, Kohn KW, Pommier Y. 2006. $p21^{CDKNIA}$ allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydro xystaurosporine. Oncogene. 25: 2839-2849. https://doi.org/10.1038/sj.onc.1209313
  14. Giannakakou P, Robey R, Fojo T, Blagosklonny MY. 2001. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene. 20: 3806-3813. https://doi.org/10.1038/sj.onc.1204487
  15. Gupta M, Fan S, Zhan O, Kohn KW, O'Connor PM, Pommier Y. 1997. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin Cancer Res. 3: 1653-1660.
  16. Han Z, Wei W, Dunaway S, Darnowski JW, Calabresi P, Sedivy J, Hendrickson EA, Balan KV, Pantazis P, Wyche JH. 2002. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem. 77: 17154-17160.
  17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics. CA Cancer J Clin. 58: 71-96. https://doi.org/10.3322/CA.2007.0010
  18. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK. 1996. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst. 88: 734 741. https://doi.org/10.1093/jnci/88.11.734
  19. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. 1994. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 86: 441-446. https://doi.org/10.1093/jnci/86.6.441
  20. Manfredi JJ, Parness J, Horwitz SB. 1982. Taxol binds to cellular microtubules. J Cell Biol. 94: 688-696. https://doi.org/10.1083/jcb.94.3.688
  21. Pommier Y. 2006. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 6: 789-802. https://doi.org/10.1038/nrc1977
  22. Pommier Y, Redon C, Rao VA, Seiler JA, Sordet O, Takemura H, Antony S, Meng L, Liao Z, Kohlhagen G, et al. 2003. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res. 532: 173-203. https://doi.org/10.1016/j.mrfmmm.2003.08.016
  23. Satou M, Aizawa S, Hayakari M, Ookawa K, Tsuchida S. 2003. Enhanced sensitivity to cis-diamminedichloro-platinum(II) of a human carcinoma cell line with mutated p53 gene by cycIin-dependent kinase inhibitor p21WAF1 expression. Cancer Sci. 94:286-291. https://doi.org/10.1111/j.1349-7006.2003.tb01434.x
  24. Schmidt F, Schuster M, Streffer J, Schabet M, Weller M. 1999. Topotecan-based combination chemotherapy for human malignant glioma. Anticancer Res. 19:1217-1221.
  25. Segal NH, Saltz LB. 2009. Evolving treatment of advanced colon cancer. Annu Rev Med. 60: 207-219. https://doi.org/10.1146/annurev.med.60.041807.132435
  26. Shamu CE, Murray AW. 1992. Sister chromatid separation in frog egg extracts requires DNA topoisomerase II activity during anaphase. J Cell Biol. 117: 921-934. https://doi.org/10.1083/jcb.117.5.921
  27. Sinicrope FA, Roddey G, Lemoine M, Ruan S, Stephens LC, Frazier ML, Shen Y, Zhang W. 1998. Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasia but not hereditary nonpolyposis colorectal cancers. Clin Cancer Res. 4: 1251-1261.
  28. Tishler RB, Schiff PB, Geard CR, Hall EJ. 1992. Taxol: a novel radiation sensitizer. Int J Radiat Oncol BioI Phys. 22: 613-617. https://doi.org/10.1016/0360-3016(92)90888-O
  29. Torres K, Horwitz SB. 1998. Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res. 58: 3620-3626.
  30. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. 1966. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate. J Am Chem Soc. 88: 3888-3890. https://doi.org/10.1021/ja00968a057
  31. Wolpin BM, Mayer RJ. 2008. Systemic treatment of colorectal cancer. Gastroenterology. 134: 1296-1310. https://doi.org/10.1053/j.gastro.2008.02.098
  32. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ. 1995. p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med. 1: 1052-1056. https://doi.org/10.1038/nm1095-1052
  33. Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, Liu ET, Kohn KW, Pommier Y, Weinstein JN. 2002. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res. 62: 1688-1695.

피인용 문헌

  1. Anti-inflammatory actions of plant-derived multiple monoclonal antibody CO17-1A × BR55 related with anti-cancer effects in AOM/DSS-induced colorectal cancer mouse via down-regulating of ERK1/2 vol.20, pp.4, 2016, https://doi.org/10.1080/19768354.2016.1211176